84 Participants Needed

EEG for Schizophrenia

EL
Overseen ByEdmund Lalor, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are a healthy control subject or a case-match control non-ill subject, you should not have used daily antidepressants, mood stabilizers, or antipsychotic medications in the last 6 months, or benzodiazepines in the last 2 days.

What data supports the effectiveness of EEG treatment for schizophrenia?

Research shows that EEG can detect brain changes in schizophrenia, and these changes are stable over time, suggesting they are not just side effects of treatment. Additionally, EEG abnormalities have been linked to better functioning in some areas for patients consistently diagnosed with schizophrenia.12345

Is EEG generally safe for humans?

EEG (electroencephalography) is generally considered safe for humans, as it is a non-invasive method used to record brain activity. However, some studies have noted EEG abnormalities in patients taking certain medications like clozapine, which can also lead to seizures in a small percentage of cases. These findings are related to the medication rather than the EEG procedure itself.678910

How does EEG treatment for schizophrenia differ from other treatments?

EEG (electroencephalography) is unique for schizophrenia as it is a non-invasive and inexpensive method that helps to understand brain activity patterns in patients, unlike traditional drug treatments that focus on altering brain chemistry. EEG can identify specific brain wave abnormalities, which may help tailor more personalized treatment approaches.25111213

What is the purpose of this trial?

This study aims to identify novel markers of psychosis using electroencephalography (EEG).

Eligibility Criteria

This trial is for adults aged 18-65 with good English skills, visual acuity of at least 20/32, and diagnosed with Bipolar Disorder or Schizophrenia-Spectrum Disorders as per DSM-5. Excluded are those with significant head injuries, intellectual impairments, recent substance abuse or suicidal behavior, current manic states, certain neurological conditions or treatments like ECT within the last 8 weeks.

Inclusion Criteria

Subjects with 20/32 visual acuity or better (using in-house optical correction, if necessary)
Subjects with Bipolar Disorder meeting DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5)
I have been diagnosed with a type of Schizophrenia-Spectrum Disorder.

Exclusion Criteria

Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter)
Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent
Intellectual impairment (WRAT-5 score < 70) (at the discretion of experimenter)
See 19 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

EEG Assessment

Participants undergo electroencephalography (EEG) to identify novel markers of psychosis

1-2 weeks

Follow-up

Participants are monitored for safety and effectiveness after EEG assessment

4 weeks

Treatment Details

Interventions

  • EEG
Trial Overview The study uses EEG to measure visual processing in an attempt to find new markers for psychosis. Participants will be individuals diagnosed with mood disorders or at high risk for psychosis who meet specific criteria outlined by the researchers.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: All participantsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Rochester

Lead Sponsor

Trials
883
Recruited
555,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials
3,007
Recruited
2,852,000+

References

Electroencephalographic findings in relation to diagnostic constructs in psychiatry. [2022]
Resting EEG in first-episode and chronic schizophrenia. [2019]
Individual analysis of EEG band power and clinical drug response in schizophrenia. [2007]
Pretreatment EEG predicts short-term response to haloperidol treatment. [2019]
Computerized EEG in schizophrenia. [2019]
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. [2023]
Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia. [2021]
EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients. [2015]
Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free. [2019]
10.United Statespubmed.ncbi.nlm.nih.gov
Clozapine-induced seizures and EEG abnormalities in ambulatory psychiatric patients. [2017]
11.United Statespubmed.ncbi.nlm.nih.gov
A review of recent literature employing electroencephalographic techniques to study the pathophysiology, phenomenology, and treatment response of schizophrenia. [2021]
Clozapine augments delta, theta, and right frontal EEG alpha power in schizophrenic patients. [2021]
Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security